The Korean Journal of Urological Oncology (대한비뇨기종양학회지)

Korean Urological Oncology Society (대한비뇨기종양학회)
권호 표지
DOI QR코드

DOI QR Code

Relationship of Prostate-Specific Antigen Level With Obesity Indices in Korean Middle-Aged Population

  • Received : 2018.09.08
  • Accepted : 2018.10.10
  • Published : 2018.12.30
⟨ Previous Next ⟩

Abstract

Purpose: We evaluated the relationship of prostate-specific antigen (PSA) and obesity indices (weight, body mass index [BMI] and waist circumference [WC]) in Korean middle-aged men. Materials and Methods: From February to September 2013, 1,900 police men under 60 years old who participated in a prostate health screening program were included this cross-sectional study. All subjects underwent clinical examinations including weight, height, BMI, WC, fasting blood sugar, lipid profiles, estimated glomerular filtration rate (GFR), and PSA. Total prostate volume (TPV) was assessed clinically. Spearman correlation and multiple linear regression tests were performed to evaluate the obesity indices and PSA relationships. Results: The mean age was $52.0{\pm}4.7years$, and the mean PSA was $0.97{\pm}0.99ng/mL$. The PSA showed a significant positive correlation with the age (r=0.108, p<0.01), TPV (r=0.349, p<0.01), height (r=-0.052, p<0.05), weight (r=0.186, p<0.05), low-density lipoprotein cholesterol (r=0.056, p<0.05), and GFR (r=-0.096, p<0.01). All obesity indices including weight, BMI, and WC showed negative correlations with PSA (beta=-0.013, p<0.001; beta=-0.039, p<0.001; and beta=-0.010, p=0.005; respectively) in age and TPV-adjusted model. Conclusions: Common obesity indices (weight, BMI, and WC) were associated with lower PSA in Korean middle-aged population. Thus, an individual's degree of obesity should be considered when PSA is checked in the first prostate cancer screening of life.

Keywords

Acknowledgement

Supported by : National Police Hospital

References

  1. Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee JK, et al. Prediction of cancer incidence and mortality in Korea, 2016. Cancer Res Treat 2016;48:451-7. https://doi.org/10.4143/crt.2016.092
  2. Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008;17:3252-61. https://doi.org/10.1158/1055-9965.EPI-08-0609
  3. Bassett JK, Severi G, Baglietto L, MacInnis RJ, Hoang HN, Hopper JL, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer 2012;131:1711-9. https://doi.org/10.1002/ijc.27414
  4. Naito M, Asai Y, Mori A, Fukada Y, Kuwabara M, Katase S, et al. Association of obesity and diabetes with serum prostate- specific antigen levels in Japanese males. Nagoya J Med Sci 2012;74:285-92.
  5. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011;21:835-41. https://doi.org/10.1016/j.annepidem.2011.07.007
  6. Haggstrom C, Stocks T, Ulmert D, Bjorge T, Ulmer H, Hallmans G, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer 2012;118:6199-206. https://doi.org/10.1002/cncr.27677
  7. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
  8. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78. https://doi.org/10.1016/S0140-6736(08)60269-X
  9. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003. https://doi.org/10.1007/s10552-006-0049-z
  10. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006;15:1331-5. https://doi.org/10.1158/1055-9965.EPI-06-0082
  11. Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer 2003;89:1237-42. https://doi.org/10.1038/sj.bjc.6601206
  12. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007;109:675-84. https://doi.org/10.1002/cncr.22443
  13. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005;103:1092-5. https://doi.org/10.1002/cncr.20856
  14. Fowke JH, Matthews CE. PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. Prostate 2010;70:120-5.
  15. Skolarus TA, Wolin KY, Grubb RL 3rd. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol 2007;4:605-14. https://doi.org/10.1038/ncpuro0944
  16. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800-9. https://doi.org/10.1016/j.eururo.2012.11.013
  17. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002;296:2232-5. https://doi.org/10.1126/science.1073051
  18. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-15. https://doi.org/10.1158/0008-5472.CAN-07-5997
  19. Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011;223:283-94.
  20. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst 2013;105:1881-90. https://doi.org/10.1093/jnci/djt332
  21. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015;350:g7607. https://doi.org/10.1136/bmj.g7607
  22. Moreira DM, Anderson T, Gerber L, Thomas JA, Banez LL, McKeever MG, et al. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control 2011;22:977-83. https://doi.org/10.1007/s10552-011-9770-3
  23. Garcia-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, et al. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int 2012;110(11 Pt B):E541-6. https://doi.org/10.1111/j.1464-410X.2012.11232.x
  24. Morote J, Celma A, Planas J, Placer J, de Torres I, Olivan M, et al. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci 2014;15:13615-23. https://doi.org/10.3390/ijms150813615
  25. Arthur R, Moller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, et al. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med 2016;5:1307-18. https://doi.org/10.1002/cam4.665
  26. Sekine Y, Koike H, Nakano T, Nakajima K, Takahashi S, Suzuki K. Remnant lipoproteins induced proliferation of human prostate cancer cell, PC-3 but not LNCaP, via low density lipoprotein receptor. Cancer Epidemiol 2009;33:16-23. https://doi.org/10.1016/j.canep.2009.04.004
  27. Liu M, Wang JY, Zhu L, Wan G. Body mass index and serum lipid profile influence serum prostate-specific antigen in Chinese men younger than 50 years of age. Asian J Androl 2011;13:640-3. https://doi.org/10.1038/aja.2010.104